Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. has developed the RaniPill capsule, an innovative platform technology designed to deliver a wide variety of therapeutic biologics orally, significantly enhancing patient convenience and adherence compared to traditional injection methods. The company's strong partnership with Chugai validates its approach in the biotherapeutics space, positioning Rani to potentially capitalize on a lucrative global market, particularly in next-generation obesity therapies which are experiencing notable acquisition interest. Additionally, with robust preclinical data supporting the efficacy and bioavailability of its lead program RT-114 and a solid financial position enabling operations through 2028, Rani is poised for significant growth and development opportunities.

Bears say

The financial analysis indicates a negative outlook on Rani Therapeutics Holdings Inc. due to several fundamental risks, primarily stemming from potential competition that could disrupt existing revenue forecasts and impair sales of the company's product pipeline. Additionally, the reliance on achieving adequate reimbursement rates poses a significant challenge to meeting financial projections, as any shortfall could adversely affect the company's revenue expectations. Lastly, while the mechanical safety profile of the RaniPill capsule appears derisked through extensive testing, the uncertainty surrounding future clinical trial outcomes may further impact forecasts and overall valuation.

RANI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 3 analysts, RANI has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.